Published in N Engl J Med on May 05, 1994
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW - ACS) (WILLOW ACS) | NCT02741817
Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension | NCT04908982
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest (1999) 3.16
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest (2000) 1.78
Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol (2001) 1.63
Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest (1995) 1.55
Aspirin and acute myocardial infarction: clarifying the message. Br J Gen Pract (1995) 1.48
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest (2001) 1.45
Effects of atrioventricular asynchrony on platelet activation: implication of thromboembolism in paced patients. Heart (1997) 1.42
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A (2002) 1.39
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol (2001) 1.30
Why is environmental tobacco smoke more strongly associated with coronary heart disease than expected? A review of potential biases and experimental data. Environ Health Perspect (1999) 1.24
Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy. BMC Pregnancy Childbirth (2009) 1.18
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A (2003) 1.11
Platelet aggregation pathway. Pharmacogenet Genomics (2011) 1.04
Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol (2011) 1.00
Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? BMJ (1994) 0.99
Total saponin from korean red ginseng inhibits thromboxane A2 production associated microsomal enzyme activity in platelets. J Ginseng Res (2012) 0.96
Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet (2004) 0.95
Aspirin for primary prevention of cardiovascular events. J Gen Intern Med (1998) 0.94
Strictures, diaphragms, erosions or ulcerations of ischemic type in the colon should always prompt consideration of nonsteroidal anti-inflammatory drug-induced lesions. World J Gastroenterol (2005) 0.91
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag (2009) 0.90
OTC analgesics and drug interactions: clinical implications. Osteopath Med Prim Care (2008) 0.89
Pain management: Part 1: Managing acute and postoperative dental pain. Anesth Prog (2010) 0.89
Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care (2015) 0.89
Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol (2003) 0.88
COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest (2001) 0.87
Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br J Pharmacol (2001) 0.87
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol (2010) 0.86
Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family? J Biomed Sci (2010) 0.85
Characterization of a novel transcript of prostaglandin endoperoxide H synthase 1 with a tissue-specific profile of expression. Biochem J (1999) 0.85
Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (1995) 0.84
Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures. J Gastroenterol (2005) 0.84
Adverse drug interactions. Anesth Prog (2011) 0.83
Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. Br J Pharmacol (2006) 0.83
Gender differences of low-dose aspirin-associated gastroduodenal ulcer in Japanese patients. World J Gastroenterol (2010) 0.83
Cordycepin-Enriched WIB801C from Cordyceps militaris Inhibits Collagen-Induced [Ca(2+)]i Mobilization via cAMP-Dependent Phosphorylation of Inositol 1, 4, 5-Trisphosphate Receptor in Human Platelets. Biomol Ther (Seoul) (2014) 0.81
Cytosolic phospholipase A2 plays a crucial role in ROS/NO signaling during microglial activation through the lipoxygenase pathway. J Neuroinflammation (2015) 0.80
Antiplatelet therapy in cardiovascular disease. Postgrad Med J (2004) 0.80
Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs? BMC Med (2015) 0.80
Ticlopidine and aspirin interactions. Heart (1997) 0.79
A novel indazolo-triazolo-benzotriazepine exerts anti-inflammatory effects by inhibition of cyclooxygenase-2 activity and nitric oxide synthase-2 expression. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.79
Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention. Curr Control Trials Cardiovasc Med (2001) 0.79
Low molecular weight heparin in immunological recurrent abortion--the incredible cure. J Assist Reprod Genet (2003) 0.79
Salicylate, an aspirin metabolite, specifically inhibits the current mediated by glycine receptors containing alpha1-subunits. Br J Pharmacol (2009) 0.79
Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane A(2) receptor. Acta Pharmacol Sin (2010) 0.79
Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy? J Gastroenterol (2016) 0.78
Cardiovascular drugs: implications for dental practice. Part 2--antihyperlipidemics and antithrombotics. Anesth Prog (2008) 0.77
Hydrogen sulfide releasing aspirin, ACS14, attenuates high glucose-induced increased methylglyoxal and oxidative stress in cultured vascular smooth muscle cells. PLoS One (2014) 0.77
Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur J Clin Pharmacol (2003) 0.77
Giving aspirin and ibuprofen after myocardial infarction. BMJ (2003) 0.77
Small bowel injury in low-dose aspirin users. J Gastroenterol (2014) 0.76
Antiplatelet therapy. Br J Gen Pract (1996) 0.75
Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. Br J Clin Pharmacol (1999) 0.75
Personalized healthcare in clotting disorders. Per Med (2010) 0.75
Recurrent strokes under anticoagulation therapy: Sticky platelet syndrome combined with a patent foramen ovale. J Cardiovasc Dis Res (2011) 0.75
Aspirin prophylaxis for the prevention of thrombosis: expectations and limitations. Thrombosis (2012) 0.75
Evaluation of effects of various drugs on platelet functions using phorbol 12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells. Drug Des Devel Ther (2016) 0.75
In Silico Analysis of the Potential of the Active Compounds Fucoidan and Alginate Derived from Sargassum Sp. as Inhibitors of COX-1 and COX-2. Med Arch (2016) 0.75
Current developments in anti-platelet therapy. Wien Med Wochenschr (2006) 0.75
The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils. Br J Clin Pharmacol (1998) 0.75
New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myeloma Leuk (2015) 0.75
Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer. Free Radic Biol Med (2015) 0.75
Clinical Pharmacology and Cardiovascular Safety of Naproxen. Am J Cardiovasc Drugs (2016) 0.75
Antithrombotic drugs: pharmacology and implications for dental practice. Anesth Prog (2013) 0.75
Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy. J Thromb Thrombolysis (1995) 0.75
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Thromb Haemost (1995) 0.76
Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Agents Actions Suppl (1992) 0.75